PremiumThe FlyTeladoc price target lowered to $7 from $8 at BofA Teladoc’s Hold Rating Amid Declining User Base and Strategic Investments Teladoc price target lowered to $9 from $10 at Truist PremiumRatingsHold Rating for Teladoc Amid UpLift Acquisition and Adjusted EBITDA Guidance Revision Teladoc call volume above normal and directionally bullish Teladoc’s Transitional Phase: Hold Rating Amid Uncertain Long-Term Prospects PremiumRatingsTeladoc’s Strategic Moves and Financial Outlook: Hold Rating Amid Growth Potential and Margin Pressures Teladoc Health Reports Q1 2025 Financial Results Teladoc’s Transitional Phase: Hold Rating Amidst Slower Growth and Strategic Adjustments 
